Scholar Rock Holding (SRRK) Income towards Parent Company (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Income towards Parent Company of -$101.4 million for Q1 2026, down 35.42% year-over-year from -$157.1 million in Q1 2025, and down 11.21% quarter-over-quarter from -$91.2 million in Q4 2025.
Analysis
Scholar Rock Holding (SRRK) Income towards Parent Company (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$101.4 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 35.42% year-over-year to -$101.4 million; the TTM figure through Mar 2026 stood at -$717.0 million (down 168.23% YoY), while the FY2025 annual figure was -$377.7 million, down 53.37% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$101.4 million, down from -$91.2 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$9.2 million in Q1 2022, with the low at -$263.8 million in Q2 2025.
- The 5-year median for Income towards Parent Company is -$56.8 million (2024), against an average of -$80.3 million.
- The sharpest annual moves came in 2022 and 2023: Income towards Parent Company soared 93.69% in 2022, then plunged 383.1% in 2023.
- Scholar Rock Holding's Income towards Parent Company stood at -$42.1 million in 2022, then slipped by 18.84% to -$50.0 million in 2023, then sank by 32.75% to -$66.4 million in 2024, then sank by 37.37% to -$91.2 million in 2025, then declined by 11.21% to -$101.4 million in 2026.
- Business Quant data shows SRRK's Income towards Parent Company at -$101.4 million in Q1 2026, -$91.2 million in Q4 2025, and -$260.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Scholar Rock Holding | 7.24 Bn | 7.24 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -109.33 Mn |
| Mar 31, 2026 | -101.38 Mn |
| Dec 31, 2025 | -90.90 Mn |
| Sep 30, 2025 | -102.15 Mn |
| Jun 30, 2025 | -109.90 Mn |
| Mar 31, 2025 | -74.68 Mn |
| Dec 31, 2024 | -66.44 Mn |
| Sep 30, 2024 | -64.44 Mn |
| Jun 30, 2024 | -58.49 Mn |
| Mar 31, 2024 | -56.83 Mn |
| Dec 31, 2023 | -48.03 Mn |
| Sep 30, 2023 | -43.67 Mn |
| Jun 30, 2023 | -39.08 Mn |
| Mar 31, 2023 | -40.51 Mn |
| Dec 31, 2022 | -40.43 Mn |
| Sep 30, 2022 | -43.86 Mn |
| Jun 30, 2022 | -43.15 Mn |
| Mar 31, 2022 | -6.93 Mn |
| Dec 31, 2021 | -35.36 Mn |
| Sep 30, 2021 | -37.08 Mn |